The IPO is with a face value of Re 1 per equity share and is a mix of a fresh issue of up to Rs 300 crore

Temasek Holdings and TPG-backed eye care services Dr Agarwal Health Care have filed their draft red herring prospectus (DRHP) with the market regulator, the Securities and Exchange Board of India (SEBI), to raise funds through an initial public offering (IPO).

The IPO with a face value of Re 1 per equity share is a mix of a fresh issue of up to Rs 300 crore and an offer for sale of up to 69,568,204 equity shares by the promoter and other selling shareholders. The offer also includes a subscription reservation for eligible employees.

The offer for sale consists of up to 2,253,913 equity shares by Dr Amar Agarwal up to 2,704,696 equity shares by Dr Athiya Agarwal, up to 2,961,614 Equity Shares by Dr Adil Agarwal, up to 5,242,630 equity shares by Dr Anosh Agarwal, up to 230,035 equity shares by Dr Ashvin Agarwal, up to 1,963,172 equity shares by Dr Agarwal's Eye Institute, up to 7,083,010 equity shares by Arvon Investments, up to 16,148,150 equity shares by Claymore Investments (Mauritius), up to 30,755,592 equity shares by Hyperion Investments, up to 112,696 equity shares by Farah Agarwal, and up to 112,696 equity shares by Urmila Agarwal.

Kotak Mahindra Capital Company, Morgan Stanley India Company, Jefferies India and Motilal Oswal Investment Advisors are the book-running lead managers, and KFin Technologies Limited is the registrar to the offer.